Since the main entry receptor for SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2) [17], and ACE2 expression may be up-regulated by ACE inhibitors and ARBs [18], a huge scientific-pharmacological debate started about ACEI use in patients with infection or who are at high risk for severe SARS-CoV-2 infection [19,20]. This evidence concerns the gene ACE2 and infection.